Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,961 total articles

SweetWater Brewing Unveils Atlanta-Wide Soccer Celebration as Global Fans Descend on the City This Summer

SweetWater Brewing Unveils Atlanta-Wide Soccer Celebration as Global Fans Descend on the City This Summer

SweetWater Brewing, the Southeast's leading craft beer brand and subsidiary of Tilray Brands (NASDAQ: TLRY), announced a citywide soccer celebration in Atlanta for summer 2026. Leveraging Atlanta hosting major international soccer matches, the program includes stadium activations, fan experiences, exclusive beer collaborations, and watch parties to…

FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers

FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers

FibroBiologics has dosed the first patients in its Phase 1/2 clinical trial of CYWC628, a topical allogeneic fibroblast-spheroid cell therapy designed to treat diabetic foot ulcers (DFUs). The multicenter, randomized study in Australia aims to evaluate safety, tolerability, and efficacy by comparing CYWC628 plus standard of care (SoC) against SoC a…

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

Cabaletta Bio announced encouraging clinical data for its investigational autologous CAR T cell therapy, rese-cel, showing durable, immunomodulator-free responses in patients with autoimmune diseases including dermatomyositis, systemic sclerosis, and lupus. The data support advancement in registrational studies and highlight potential for precondit…

Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors

Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors

Ovid Therapeutics Inc. has appointed Dr. Anna Greka, a distinguished physician-scientist and biotech innovator, to its Board of Directors. Dr. Greka will chair Ovid's new Science and Technology Committee and contribute to advancing Ovid's pipeline of targeted therapies for neurological and neuropsychiatric disorders, including epilepsy and KCC2 act…

Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

Cocrystal Pharma Inc., a clinical-stage biotech company specializing in antiviral therapeutics, has named James Sapirstein as its new CEO effective immediately. Sapirstein brings extensive leadership experience in pharmaceutical development and commercialization, having led multiple product launches and held senior roles at major biopharma companie…

Destination XL Group, Inc. Reports First Quarter Financial Results

Destination XL Group, Inc. Reports First Quarter Financial Results

Destination XL Group, Inc. reported first quarter fiscal 2026 results with total sales declining 2.1% to $103.3 million and a net loss of $5.9 million compared to $1.9 million loss a year prior. The company is focused on strategic initiatives such as expanding its proprietary FiTMAP fit technology and leveraging AI to improve e-commerce discoverabi…

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms

Tenaya Therapeutics announced encouraging interim data from its MyPEAK-1 Phase 1b/2 clinical trial evaluating TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM). The treatment showed consistent improvements in cardiac remodeling, reduction of left ventricular hypertrophy, symptom relief, and increased exercise capacity acro…

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Kura Oncology reported encouraging Phase 1a clinical trial results demonstrating darlifarnib combined with adagrasib yields objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in colorectal cancer patients with KRAS mutations. The company is launching a flexible platform study to explore multiple darlifa…

Taboola Announces Inclusion in Russell 3000® and 2000® Index

Taboola Announces Inclusion in Russell 3000® and 2000® Index

Taboola, a global leader in performance advertising technology, will be included in the Russell 3000 and Russell 2000 Indexes at the close of the June 2026 Russell Reconstitution. This inclusion reflects the company's strong business fundamentals and aims to enhance visibility among institutional investors, potentially supporting long-term sharehol…

Akamai and GM Sectec Partner to Secure Autonomous Digital Workforce

Akamai and GM Sectec Partner to Secure Autonomous Digital Workforce

Akamai Technologies announced a strategic partnership with GM Sectec to integrate advanced PCI compliance and cybersecurity solutions aimed at securing AI-driven autonomous digital workforces and strengthening defenses against ransomware and API-based threats. The collaboration focuses on pioneering agentic compliance, continuous API security, and …

Amaze Launches Partnership with Country Music Powerhouse BBR Music Group to Build Commerce Storefront for Music Merchandise

Amaze Launches Partnership with Country Music Powerhouse BBR Music Group to Build Commerce Storefront for Music Merchandise

Amaze Holdings, Inc. announces a partnership with country music label BBR Music Group to create a centralized merchandise storefront for artists. Using Amaze's print-on-demand platform, the collaboration aims to provide scalable, low-risk merchandising solutions and new revenue streams for artists by enabling rapid product design and launch without…

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

MannKind Corporation announced the completion of patient randomization in its Phase 1b INFLO-1 study and enrollment of the first patient in the global Phase 2 INFLO-2 trial for its inhaled nintedanib dry powder inhaler (DPI) targeting idiopathic pulmonary fibrosis (IPF). The Phase 1b data, expected in Q3 2026, will assess safety, tolerability, and …